Liver: A Target of Late Diabetic Complications

Abstract

Whereas many studies have implicated metabolic liver dysfunction as a causative factor for obesity-related type 2 diabetes and the Metabolic Syndrome, its role as a long-term complication of diabetic metabolism is still mostly unexplored.

In contrast to the well-described late diabetic micro- and macro-vascular complications in response to hyperglycemic conditions such as nephro- and retinopathy as well as atherosclerosis, only recent studies have highlighted disturbances of liver function as a novel aspect of diabetic late complications that may substantially impact the overall disease outcome and determine mortality rates in diabetic subjects. Here we will discuss recent developments in this area, particularly focusing on transcriptional regulators of hepatic dysfunction as a long-term consequence of established diabetes.

Key words

transcription factor - diabetic late complications - liver

• References

• 1 Rose AJ, Vegiopoulos A, Herzig S. Role of glucocorticoids and the glucocorticoid receptor in metabolism: insights from genetic manipulations. J Steroid Biochem Mol Biol 2010; 122: 10-20
• 2 Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis 2004; 8: 501-519 vii
• 3 Fabbrini E, Magkos F, Mohammed BS et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106: 15430-15435
• 4 Wang MY, Chen L, Clark GO et al. Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci USA 2010; 107: 4813-4819
• 5 Manna P, Das J, Ghosh J et al. Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways: Prophylactic role of arjunolic acid. Free Radic Biol Med 2010; 48: 1465-1484
• 6 Dennis MD, Schrufer TL, Bronson SK et al. Hyperglycemia-induced O-GlcNAcylation and truncation of 4E-BP1 protein in liver of a mouse model of type 1 diabetes. J Biol Chem 2011; 286: 34286-34297
• 7 Bulum T, Kolaric B, Duvnjak L et al. Nonalcoholic Fatty Liver Disease Markers Are Associated with Insulin Resistance in Type 1 Diabetes. Dig Dis Sci 2011;
• 8 Targher G, Bertolini L, Padovani R et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010; 53: 713-718
• 9 Shimomura I, Bashmakov Y, Ikemoto S et al. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci USA 1999; 96: 13656-13661
• 10 Gaens KH, Niessen PM, Rensen SS et al. Endogenous formation of N(epsilon)-(carboxymethyl)lysine is increased in fatty livers and induces inflammatory markers in an in vitro model of hepatic steatosis. J Hepatol 2011;
• 11 Kim JY, Lee SH, Song EH et al. A critical role of STAT1 in streptozotocin-induced diabetic liver injury in mice: controlled by ATF3. Cell Signal 2009; 21: 1758-1767
• 12 Aleksunes LM, Reisman SA, Yeager RL et al. Nuclear factor erythroid 2-related factor 2 deletion impairs glucose tolerance and exacerbates hyperglycemia in type 1 diabetic mice. J Pharmacol Exp Ther 2010; 333: 140-151
• 13 Pei L, Waki H, Vaitheesvaran B et al. NR4A orphan nuclear receptors are transcriptional regulators of hepatic glucose metabolism. Nat Med 2006; 12: 1048-1055
• 14 Dong B, Qatanani M, Moore DD. Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes. Hepatology 2009; 50: 622-629
• 15 Yao D, Taguchi T, Matsumura T et al. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem 2007; 282: 31038-31045
• 16 Mizutani N, Ozaki N, Seino Y et al. Reduction of Insulin Signaling Upregulates Angiopoietin-like Protein 4 Through Elevated Free Fatty Acids in Diabetic Mice. Exp Clin Endocrinol Diabetes 2011;